Recent scientific discoveries that are an outcome of next generation sequencing technology show the impact of massively parallel platforms. The declining cost of genomic sequencing has paved way for the clinical application of this technology. The tremendous growth in drug discovery and molecular diagnostics will promote the uptake of this technology.
New analysis from Frost & Sullivan (pharma.frost.com), European Next Generation Sequencing Markets, finds that the markets earned revenues of $278.3 million in 2010 and estimates this to reach $1,042.2 billion in 2017 due to the increased focus on human genome sequencing and the application of this technology to disease prediction. The segments covered include sequencing within the service providing sector and academic research laboratories.
"NGS are rapidly replacing microarray technology in key applications," notes Frost & Sullivan Research Analyst Divyaa Ravishankar. "Enhanced breadth of application is contributing, in turn, to wider coverage even as increased read lengths are being worked on in the new platforms."
The urge to sequence complex and variable human genomes has created opportunities for the growth of next generation sequencing in areas like gene discovery, gene expression, gene regulation studies and clinical diagnostic applications in Europe.
An increasing number of laboratories in Europe are replacing microarrays with NGS. Ongoing cancer research programmes, biomarker discovery, forensics and many funded drug discovery projects rely on NGS. Around 130 research centres in Europe are using this technology.
However, funding and technology related issues remain areas of concern. European research organisations are dependent on funding and grants. These are sometimes in short supply, posing problems for continued research. At the same time, technology overlapping by various NGS vendors raises IP concerns.
"There is significant concern regarding technology overlap since all the market participants have common goals that include sample preparation methods, higher throughput and cost-cutting measures," explains Ravishankar. "Competitors are moving towards longer reads and single molecule real-time sequencing (SMRT) and hence, the need to patent their technology is becoming a key issue."
Increase in the volume of data requiring efficient data management systems poses a challenge. At the same time, interpretation of complex data from next-generation platforms looms as another challenge that market participants and end users will need to tackle.
Applications for next generation sequencing can be better addressed with a multidisciplinary approach that embraces novel solutions and innovative technologies. Developing instruments that will cater to end-user needs will enable market participants to gain an edge.
"Concentrating on factors like greater read lengths, higher throughput and improved accuracy will help companies succeed," concludes Ravishankar. "Instrument pricing can also help promote sales."
For more information on this study, please send your complete contact details to Chiara Carella, Corporate Communications, at chiara.carella[.]frost.com.
European Next Generation Sequencing Markets is part of the Pharmaceuticals & Biotechnology Growth Partnership Services programme, which also includes research in the following markets: European DNA Microarray Market and European Cancer Support Therapies Market. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents.
European Next Generation Sequencing Markets / M691